<DOC>
	<DOCNO>NCT00783328</DOCNO>
	<brief_summary>To evaluate safety tolerability PF-00299804 Japanese patient advanced malignant solid tumor dose clinically recommended phase 2 dose non-Japanese study .</brief_summary>
	<brief_title>A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Malignant solid tumor currently approve treatment Adequate function Bone Marrow , Renal , Liver Cardiac Any surgery , radiotherapy within 4 week baseline disease assessment Clinically significant abnormality cornea Patients symptomatic brain/central nerve system metastases Any clinically significant gastrointestinal abnormality Uncontrolled significant cardiovascular disease Patients significant interstitial pneumonia pulmonary fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>solid tumor</keyword>
</DOC>